John J. Powers

Moffitt Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.4kcitations233works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(51), Immunotherapy and Immune Responses(44), Chronic Lymphocytic Leukemia Research(35), Cancer Immunotherapy and Biomarkers(32), Immune Cell Function and Interaction(25)

Publications233 total

Collagen remodeling promotes a GPCR-mediated mechanosensory immune checkpoint in ADGRG1+ CD8+ T cells and serves as a spatial biomarker of response to immunotherapy
2025
Adaptive Responses Directed by CREB Control Epithelial-Mesenchymal Plasticity in Cancer
2025
An FGFR-p53 developmental signaling axis drives salivary cancer progression
UNC Libraries·2025Open Access
Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progression
UNC Libraries·2025Open Access
Exploratory Case Series Assessing the Potential Interaction Between Lithium and Sodium-Glucose Cotransporter-2 Inhibitors
Journal of Clinical Psychopharmacology·2025· 1 cited
Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL
Blood Advances·2025· 4 citedOpen Access
Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progression
Oncogene·2025Open Access
An FGFR-p53 developmental signaling axis drives salivary cancer progression
Oncogene·2025· 1 citedOpen Access
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model
Blood Advances·2025· 7 citedOpen Access
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
Nature Medicine·2024· 24 citedOpen Access
Optimized in vivo multispectral bioluminescent imaging of tumor biology using engineered BRET reporters
iScience·2024· 4 citedOpen Access
Abstract 3911: A FGFR-p53 developmental signaling axis drives progression of salivary cancer
Cancer Research·2024
Abstract 5571: Collagen stabilization directs immune suppression in the head and neck squamous cell carcinoma hypoxic subtype
Cancer Research·2024
Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid Structures
2024Open Access
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers
Immunity·2023· 38 citedOpen Access
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma (1286)
Gynecologic Oncology·2023Open Access
Olfactory receptor OR5V1 is an effective target for second generation and novel NKG2D-based CAR T cells in epithelial gynecologic tumors (184)
Gynecologic Oncology·2023Open Access
Sézary syndrome originates from heavily mutated hematopoietic progenitors
Blood Advances·2023· 12 citedOpen Access
A Novel Humanized Immune Stroma PDX Cancer Model for Therapeutic Studies
2023· 3 citedOpen Access
Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC).
Journal of Clinical Oncology·2023· 2 cited
page 1 of 12Next →

Frequent Co-authors

Javier Pinilla‐Ibarz(19), Eduardo M. Sotomayor(13), Eva Sahakian(12), Alejandro Villagra(8), Fengdong Cheng(7), José R. Conejo-García(6), Ricardo A. Chaurio(5), Carmen M. Anadon(5), Subir Biswas(5), Carly M. Harro(5), Kimberly B. Sprenger(5), Jessica A. Mine(5), Patrick Innamarato(5), Gunjan Mandal(5), Xiaoqing Yu(5), Paulo C. Rodrı́guez(5), Tessa Knox(4), Karrune Woan(4), Susan Deng(4), Alan P. Kozikowski(4)